In the eBC setting, the early breast cancer setting, we've already reached 52% in NBRx share within three months of launch. And so we're getting very positive feedback from physicians and seeing ...

肉毒毒素业务2024年全年净销售额为 12.85 亿美元，按固定汇率计算，同比增长 11.8%。高德美在肉毒毒素市场持续提高市场份额，增速领先行业平均水平。欧洲市场的需求强劲，高德美的领导地位得到巩固；拉丁美洲市场表现尤为突出，远超市场平均水平；美国和中国市场的市场份额显著提高。新型液态 A 型肉毒毒素（此前称为 QM-1114）在欧洲实现首次销售，并于第四季度正式推出。

And if you recall from last year when we had another expansion, we started to see the impact of that team towards the end of Q1, which initially showed up as incremental growth in weekly NBRx or ...

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year ...

Phathom Pharmaceuticals Inc (PHAT) reported a significant increase in revenue for Q4 2024, with net revenues reaching $29.7 million, marking an 81% sequential increase. Despite the positive revenue ...

Axsome's Q4 2024 EPS and revenue missed analyst forecasts. The stock declined by 1.64% in premarket trading. The company reported a significant year-over-year growth of 6,688% in total product ...